DNA Biomed Solns (DNA) — Cash Flow Quality Index
DNA Biomed Solns (DNA) has a Cash Flow Quality Index of -0.21x as of June 2023. Operating cash flow of ILA-265.00K is below net income of ILA1.27 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DNA operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
DNA Biomed Solns Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for DNA Biomed Solns across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check DNA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for DNA Biomed Solns (2017–2024)
Year-by-year earnings quality comparison for DNA Biomed Solns. For live market cap and the full company financial profile, see market value of DNA Biomed Solns.
| Year | Quality Index | Operating CF (ILA) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | ILA1.61 Million | ILA22.10 Million | ▲ +157.4% |
| 2021 | -0.13x | ILA-2.33 Million | ILA18.37 Million | ▼ -881.3% |
| 2017 | -0.01x | ILA-1.91 Million | ILA147.36 Million | — |